title: Keith Blundy.
abstract: The non-profit Cancer Research UK (CRUK) funds over £300 million worth of cancer research each year and, with the help of its development and commercialization arm Cancer Research Technology (CRT), has moved more than 30 partnered agents into preclinical and clinical development. Having established a small-molecule track record, CRUK now needs to build up more biologic know-how, says CRT Chief Executive Officer Keith Blundy. To this end, CRUK and AstraZeneca's antibody subsidiary, MedImmune, agreed in September to launch the joint CRUK-MEDI Alliance Laboratory. This fully collaborative and integrated partnership is a first of its kind, Blundy tells Asher Mullard.
authors.forename: Keith
authors.initials: K
authors.lastname: Blundy
authors.forename: Asher
authors.initials: A
authors.lastname: Mullard
mesh_terms: D035843:Biomedical Research; D002986:Clinical Trials as Topic; D003299:Cooperative Behavior; D006801:Humans; D009939:Organizations, Nonprofit; D006113:United Kingdom